Phathom Pharmaceuticals
PHAT
94 hedge funds and large institutions have $334M invested in Phathom Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 18 closing their positions.
63,800% more call options, than puts
Call options by funds: $1.92M | Put options by funds: $3K
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
41% more capital invested
Capital invested by funds: $237M → $334M (+$97.6M)
7.06% more ownership
Funds ownership: 69.98% → 77.04% (+7.1%)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 94 → 94 (0)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
Top Sellers
PHAT Hedge Fund Activity: Q3 2022 in Review
94 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2022, worth a combined $334M — up 41% from $237M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PHAT positions and 18 closed out — a net gain of 1 holder — while 34 added to existing stakes and 23 trimmed.
The largest buyer was Frazier Life Sciences Management, adding an estimated $24.6M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $9.22M sold.
- 94 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $334M of Phathom Pharmaceuticals stock for Q3 2022, up 41% quarter-over-quarter.
- 19 funds opened new Phathom Pharmaceuticals positions in Q3 2022 and 18 closed out, a net change of +1 holder.
- The largest Phathom Pharmaceuticals buyer in Q3 2022 was Frazier Life Sciences Management, an estimated $24.6M added.
- The largest Phathom Pharmaceuticals seller in Q3 2022 was Janus Henderson Group, an estimated $9.22M sold.
Based on aggregated 13F filings for Q3 2022.